Choose a language and wait for the translated text.
Shots:
Merck KGaA has signed a definitive agreement to divest the CDMO business of its Life Science sector to Lonza for a mid-triple-digit million-euro amount, with closing expected in mid-2027, subject to regulatory approvals & other conditions
The deal covers development & manufacturing services for complex modalities across sites in Carlsbad (CA), Madison & Verona (WI), bioconjugation operations in St. Louis (MO) & Indianapolis (IN); BioReliance Contract Testing Services remains with Merck
The divestment sharpens Merck’s Life Science focus on innovation-driven businesses, while adding US manufacturing capacity & capabilities to Lonza
Ref: GlobeNewswire | Image: Merck KGaA | Lonza | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Merck KGaA to Divest its CDMO Business to Lonza appeared first on PharmaShots.
